Research suggests a daily GLP-1 pill could be a promising option for weight management. The results indicate a potential alternative to injectable weight loss treatments. Health tracking apps like Shotlee can help monitor progress.
Research indicates that a new daily GLP-1 pill is showing encouraging results in weight loss. The findings suggest a potential new option for individuals seeking to manage their weight more effectively.
The study highlights the possibility of an alternative to injectable medications for weight reduction. Health tracking apps like Shotlee can help monitor adherence and progress.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
These results offer a promising avenue for future weight management strategies. Further research is needed to fully understand the long-term effects and benefits.
Original source: News Directory 3
View original article →
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
